ADC Therapeutics (ADCT) Q2 2026 Earnings Call: LOTIS-5 FDA Concerns, $219.1M Cash
Source Tradingkey
Key Takeaways
- ZYNLONTA net product revenue was $18.6 million in Q2 2026, compared with $18.1 million in Q2 2025. Management said sales volume remained consistent with recent quarters.
- The Phase III LOTIS-5 trial met its primary progression-free survival endpoint, but the FDA raised substantial concerns about benefit-risk and verification of clinical benefit. ADC Therapeutics is evaluating additional data, risk-management measures and potential label modifications.
- LOTIS-7 completed enrollment of 100 patients at the 150 micrograms per kg dose of ZYNLONTA plus glofitamab. The company submitted data to ASH and plans to seek breakthrough therapy designation in 2026.
- Q2 GAAP net loss narrowed to $16.6 million from $56.6 million a year earlier. Adjusted net loss fell to $16.3 million from $28.7 million, mainly due to lower operating expenses.
- Cash and cash equivalents totaled $219.1 million at quarter-end. Management expects the cash runway to extend at least into 2028.
- A strategic reorganization reduced the workforce by approximately 17% and is expected to generate about $10 million in annualized cost savings.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 / Prior Period | Commentary |
|---|---|---|---|
| ZYNLONTA net product revenue | $18.6 million | $18.1 million | Management described commercial performance as broadly consistent with recent quarters |
| Cost of product sales | $2.3 million | $0.8 million | Increase mainly reflected personnel shifting from R&D clinical supply work to commercial manufacturing |
| Total operating expenses | $44.7 million | — | GAAP basis |
| Adjusted operating expenses | $37.2 million | Down 22% year over year | Decline primarily driven by lower R&D expenses |
| GAAP net loss | $16.6 million | $56.6 million | Both periods included restructuring-related effects |
| Adjusted net loss | $16.3 million | $28.7 million | Improvement primarily reflected lower operating expenses |
| Cash and cash equivalents | $219.1 million | $231.0 million at March 31, 2026 | Sequential decline primarily reflected cash used in operations |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Oil prices surged 5% following direct Israel-Iran strikes, while gold tumbled below $4,300 as a blowout U.S. jobs report fueled intense market anxieties over a December Federal Reserve rate hike.
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
Intel Corporation (NASDAQ: INTC) sits at $140.05, holding firm on the ascending trendline within the 2H timeframe. The RSI indicator is currently reading 55.21, positioning it as neutral-
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
